medicines for europe
better access. better health.

28th ANNUAL CONFERENCE
HILTON MALTA HOTEL
MALTA | 14-16 JUNE 2023
#ACCESSFORALL

Speaker, Chair and Panellist CVs

Adrian van den Hoven - Director General, Medicines for Europe

Adrian van den Hoven has been director general of Medicines for Europe since September 2013. In his role he focuses on stimulating competition in off-patent medicine markets, fostering access to medicine, reducing medicine shortages and addressing major health crises, supporting policy measures for sustainable pricing, promoting efficient regulatory standards, and developing a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value-added medicines industries. He is also member, and former president, of the European Medicines Verification Organization (EMVO) board for the implementation of serialization against falsified medicines, the vice-chair of the International Generic and Biosimilar medicines Association (IGBA) and a member of the joint industry advisory council of the Health Emergency and Response Authority (HERA).

Ana Nicholls - Director of Industry Operations, The Economist Intelligence Unit

Ana oversees the EIU's industry intelligence and forecasting from The Economist Group's London office. She manages a global team delivering reports, data and forecasts across six industry sectors: automotive, consumer goods, energy, finance, healthcare and technology. An experienced analyst specialising in global economic development, Ana is an expert on government industrial and business policy. Ana has worked closely with numerous clients in the healthcare and automotive sector, particularly on projects relating to international trade and industrial strategy. In the past year alone, Ana has delivered client presentations on macro-economic and business trends in North America and the Middle East, as well as the outlook for Asia. She has also delivered projects on incentives for energy investment, and webinars on subjects from sustainability to digitalisation. As well as her work with EIU, Ana is also a regular contributor to The Economist's annual World Ahead reports, giving industry forecasts for the year ahead.

Christopher Fearne - Deputy Prime Minister and Minister for Health of Malta

Hon. Chris Fearne is the Deputy Prime Minister of Malta and the Minister for Health. He is one of the longest standing Health Ministers in Europe as he has been at the helm of the Health Ministry since April 2014. DPM Fearne is also a member of the Global Leaders Group on Antimicrobial Resistance. He has been a Member of Parliament for the ruling Labour Party since 2013. Prior to becoming the Leader of the House, he was the Chairman of the Foreign and European Affairs Committee at the Maltese House of Representatives. Before entering the political arena, DPM Fearne worked as a doctor and surgeon for over 30 years during which he held the position of Consultant Paediatric Surgeon and Clinical Chairman at Mater Dei Hospital. He received his formal education at the University of Malta graduating in Medicine and Surgery in 1987, becoming a Fellow of The Royal College of Surgeons of Edinburgh. He worked and studied in a number of children's hospitals in England, including the Great Ormond Street Hospital in London. He also lectured students of medicine at the University of Malta. DPM Fearne is married to Astrid, also a doctor focusing on paediatric primary care. They have 3 children, Dawn, Julian and Rafael and 2 grandsons.

Elisabeth Stampa - Board Member at Medichem and President Medicines for Europe

With more than twenty years in the industry and as an experienced business leader with track record in growing and transforming businesses, Elisabeth serves currently at the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player. She held other executive positions at Corporate family business (Medichem SA and the former Combino Pharm SL), having started her career at Laboratorios Esteve. She holds a BSc in Pharmacy (UB, Spain) and a MBA (ESADE, Barcelona, Spain). She also serves on the Board of Trustees at the IQS in Barcelona. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry at a global level.

Dr Miriam Dalli - Minister for the Environment, Energy and Enterprise

Dr Miriam Dalli was appointed Minister for Energy, Enterprise and Sustainable Development in November 2020. She is responsible for the country's energy agenda, supporting businesses and pushing Malta's aims under the Sustainable Development Goals. Her vision is to align the islands' economic success with the concept of sustainability. Her aim is to attract new types of investment, sustain new economies and incentivize the green economy. Her work is geared towards the attainment of carbon neutrality by 2050 and the implementation of the UN's established Sustainable Development Goals. Miriam Dalli served as a Member of the European Parliament between May 2014 and October 2020, on behalf of the Labour Party. She served as a member of the Environment, Public Health and Food Safety Committee, the Committee on

Civil Liberties, Justice and Home Affairs and the Delegation to the EU Parliamentary Assembly for the Mediterranean. Dr Dalli first contested the European Elections in 2014 and has never ceased to promote sustainability. As vice-chair of the Socialists and Democrats, she was responsible for the Group's position on the European Green Deal. She pushed for policies that ensure competitiveness and sustainability in the various economic sectors. Amongst other work, Miriam Dalli spearheaded the EU's regulation on reducing CO2 emissions from cars and vans, and worked on the EU's position on single-use plastics and pesticides. Miriam Dalli successfully completed her Doctorate of Law at the University of Malta and she obtained a first class degree in her LL.B. course which leads to the conferment of Bachelor of Laws. She is a Communications graduate (University of Malta, 1998) and she obtained an MA in European Studies (University of Malta, 2003) and an MBA (University of Malta, 2001).

Prof. John Yfantopoulos - President IPOKE, Professor University of Athens, School of Economics and Political Science

Prof Dr John Yfantopoulos is Professor of Social Policy and Health Economics at the University of Athens, President of the ISPOR the Greek Chapter, former President of the National Centre for Social Research, and ex-President of the Board for Public Health in Greece. Prof Dr John Yfantopoulos received his Doctor of Philosophy in Health Economics from the University of York, UK. Professor Yfantopoulos has extensive teaching and research experience in Health Economics, Health Technology Assessment (HTA) and Pharmaco-economics in Europe and the USA. Professor Dr Yfantopoulos collaborated closely with the HIVA Institute (Onderzoeksinstituut voor arbeid en samenleving- Research Institute for Work and Society) which is a Belgian-based multi-disciplinary research institute at the Catholic University of Leuven. With a Group of European Experts conducted pioneered comparativestudies on long-term care, called at that time 'services for the elderly' and 'social protection of dependent older persons'. He further participated in European comparative studies on European economic integration and social protection. In this context he conducted European comparative studies and participated in conferences on the development of the welfare state in the (now 28) member states of the EU since the completion of the internal market in 1992. European comparative projects and conferences on 'The State of the Welfare State in the EU' have been organised in the following years: 1992, 1995, 2000, 2005, 2010 and 2015. Those projects wanted also to create a network or community of researchers involved in the study of the relation between European integration and the national systems of social protection. His research focuses on comparative analysis of pharmaceutical systems across Europe.

Olga Solomon - Head of Unit D1: Policy, Authorisation and Monitoring, Directorate for Health, European Commission

Olga Solomon studied Chemistry at the Aristotle University of Thessaloniki, Greece and holds an MSc in Food Science from the Gothenburg University, Sweden. Before joining the European Commission she worked for 5 years for a beverage producing company in Greece. She joined DG SANCO in 2000 and worked for 10 years in the field of Food Safety in particular dealing with legislation on Food Contact Materials, Food Additives and Enzymes. In 2010, she moved to the Directorate 'Health Systems and Products' where she worked in the field of substances of human origin before taking up a post in the pharmaceutical sector in 2011. She is currently the Head of the DG SANTE Unit responsible for Medicines: policy, authorisation and monitoring.

Radu Gănescu - President, national Coalition of organisations for patients with chronic conditions of Romania (COPAC) and Treasurer of the EPF Board

He was born in 1977, in Romania of a communist era. The first steps were difficult, at age of 7 months, Radu was diagnosticated with a Major Thalassemia, a rare hematologic disease, at that time unknown even for physicians. Still, the involvement of patients leads to a normal life for the young boy, with weekly visits to Bucharest hospitals and many treatments. Radu graduated the primary school and high school in Campina, a small town in the mountain area. After that, he moved to Bucharest for faculty. He attended the financial accounting courses, but he was forces to quit at final exams because he was forced to stay 2 years in bed due to the health condition, he wasn't able to walk by himself at that time. In 2004, after a very difficult period, he was willing to do something in order to change an un-wieldy health care system that didn't offer him a lot of choices for his suffering. He founded Association of People with Major Thalassemia, together with other patients. In 2006, the association became a member of International Federation of Thalassemia, international organization that helped us to see that patients can be treated with modern options, according to international guidelines. That was the moment that he realized that only with other patients' organization, can become a loud voice and to be a real partner for authorities. In 2008, we become members of National Alliance of Rare Disease and in 2010 of Coalition of Patients Organization with Chronic Disease, that become European Patients' Forum member from 2011and from there in 2013 he was elected president of Coalition of Patients Organization with Chronic Disease and kept this position until now. In the last 7 years, together with the team, he increased awareness on patient's rights, developed many information's campaign and raise the number of patient's organization. He was dedicated to protect the Romanian patient's rights regarding the access to treatment and medical services maintaining the quality of healthcare system. From 2014, Radu Ganescu became member of European Patient Forum board, first as treasurer 2016 and vice-president in 2018. That was an opportunity to share from his experience and implement his knowledge in the finance domain, working closed with the secretariat. Involving him in projects of great interested like capacity building for patient's association or long life vaccination for chronic patients, or clinical studies like a big part of patients access to innovation. For the moment in 2023, Coalition of Patients Organization with Chronic Disease is involved in 2 major projects of screening of cardiovascular disease and cancer at national level, project that are made with European funds and realize in partnerships with different stakeholders like medical society or national institutions.

Monica Fletcher OBE, FERS, FQNI, MSc, PGCE, DipN - Honorary Research Fellow, Usher Institute, University of Edinburgh

Advocacy Lead Asthma UK Centre for Applied Research (AUKCAR), Partnerships & Sustainability Lead for BREATHE HDRUK Respiratory Datahub and is invoved in several large grants focussed on digital and data innovations in health. She was the only nurse a team of GSK Global Respiratory Medical Experts. She was CEO of Education for Health, an international not for profit organisation, for 17 years which focussed on education and research in long term conditions. Monica is passionate about engaging those living with long term medical conditions in decisions about their health and was Chair of the European Lung Foundation and Chair of the UK Inhaler Group. Monica has wide experience of advocacy from a National, European and Global level through membership of the World Health Organisation Global Alliance Against Respiratory Disease (GARD), the American Thoracic Society and the European Respiratory Society.

Thomas Weigold - Country President, Sandoz Germany

Thomas Weigold has been appointed Country President Sandoz Germany and Managing Director Hexal AG as of January 2023. Before leading the German Sandoz organization, Thomas was the Country Head of Sandoz Poland and Chairman of Sandoz Polska Sp. z o.o. since August 2020. Prior to that, he held senior leadership roles within the Novartis Group in 8 countries around the globe including China, US, Singapore, Switzerland, and Sweden. Thomas has extensive experience in leading complex and large commercial organizations in western and emerging countries. Since 1999 he has been in various positions in the Pharma, Oncology and Sandoz Divisions of Novartis. Thomas also served as president and as member on supervisory boards of various industry associations in Europe and Asia, engaging in numerous projects on improving access to medicines for patients. In April 2023 he was elected to the ProGenerika Supervisory Board in Germany. Thomas holds a bachelor's degree in business administration (Duale Hochschule Baden Wuerttemberg) together with diverse management trainings from the University of St. Gallen, Harvard, and the Tuck University in New England.

Frances (Fran) M. Zipp - President & CEO, Lachman Consultant Services, Inc.

Fran Zipp is President & CEO of Lachman Consultant Services, Inc. As an expert in compliance enhancement, she develops program solutions to meet GXP compliance requirements and delivers strategic guidance and direction toward implementation of effective solutions to client needs. Ms. Zipp has extensive experience in the pharmaceutical, biologic and biotechnology industries from R&D through post-market approval. She assists and counsels Senior-level management in areas of Corporate Governance, Corporate Integrity Agreement Compliance, Consent Decree Negotiations and Resolutions, Application Integrity Policy resolution, and Due Diligence evaluations (facilities; products; technologies).

Kurt Farrugia - Chief Executive Officer, Malta Enterprise

Kurt Farrugia was appointed Chief Executive Officer of Malta Enterprise on 1st August 2019. Previously, he served as Head of Government Communication and spokesperson for the Prime Minister between 2013 and 2019. In August 2017, the Prime Minister appointed Mr Farrugia on the Malta-UK Business Promotion Task Force where he actively contributed on matters related to investment promotion in the UK. In April 2019 he was appointed on the New Economic Niches Committee of Malta Enterprise. Mr Farrugia formed part of the Task Force organising the Valletta Summit on Migration and the Commonwealth Head of Governments Meeting held in 2015, as well as the Informal European Council during Malta's Presidency of the Council of the European Union in February 2017.

He accompanied the Prime Minister in most of his international engagements at EU level. Mr Farrugia's career before his role at the Office of the Prime Minister was in journalism and politics. He graduated in Communications and obtained a Masters Degree in Entrepreneurship at the University of Malta.

Hubert Gambs - Deputy Director-General, Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, European Commission

Hubert Gambs is the Deputy Director-General & SME coordinator in the Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs of the European Commission since July 2020. Before he was working in various areas of the Commission (maritime affairs and fisheries, regional policy, external relations and competition policy). Hubert is Austrian and studied law in Innsbruck, Paris and Madrid.

Marion Zammit - Chief FDI Specialist, Malta Enterprise

Marion Zammit heads the Investment Promotion Department within Malta Enterprise, Malta's economic development corporation. Marion holds a First Class Bachelor's Degree in Biology and Chemistry from the University of Malta, and a Masters Degree in Business Administration (Distinction) from the same University. Her career has included various positions in the advanced manufacturing sector, including quality, production processing, as well as logistics and supply chain. Marion has worked and gained extensive experience in the Pharmaceutical Sector, having worked both in manufacturing, as well as, sales and marketing, wherein she devoted over a decade of her career. At Malta Enterprise, Marion has supported various sectors including Medical Cannabis, Pharma, and other projects of national interest. Over the past three years, Marion has been focusing specifically on the Medical Cannabis Sector, working very closely with all the stakeholders, in order to ensure an effective roll-out of the strategy for this new ecosystem in the Maltese Economy. In June 2021, Marion has been assigned the lead of the Investment Promotion Unit, hence a more prominent role in Malta's FDI Strategy and its implementation. Marion has been invited to various International Conferences as a Speaker and has contributed to articles and interviews in various renown publications.

Theodore E. Tryfon - President of PEF & Co/CEO Elpen Group

Theodore E. Tryfon was born in Mytilini – Lesvos. He holds an MBA degree from the City University of London Business School. Since 1992 he joined Elpen Pharmaceutical Co. Inc., one of the leading Pharmaceutical Industries in Greece and currently is Co/CEO of the Elpen Group. He has played a key role in the growth of the Elpen Group with a turnover of 300.000.000€ in 2022 and more than 1350 employees in Greece and abroad. Elpen exports in more than 40 countries and has a subsidiary in Germany, Elpen GmbH. He is currently the President of the Panhellenic Union of Pharmaceutical Industries (PEF) since 2014, an association which represents 49 companies with 45 production sites throughout Greece. Since April 2019 he is a Member of the Board of Directors of the Hellenic Federation of Enterprises (SEV). In 2019 he became a member of the Board of Directors of Medicines for Europe.

Arnaud Maheas - Head Public Affairs Europe, Sandoz

Arnaud is a highly experienced public affairs professional with a successful track record across multiple industries. He built and led the European public affairs practice at Servier. And prior to joining the healthcare industry 15 years ago, he headed the EU representation of the French national railway company (SNCF) and later managed strategic relations with the EU for the association of the top 100 companies operating in France (AFEP). Arnaud holds a Master of Arts in European Administration and Politics from the College of Europe in Bruges and degrees in European Law and Government Affairs from the University of Rennes and Sciences Po Rennes.

Katarina Patavou - Head of European Public Affairs & Social Impact Strategist, Panhellenic Union of Pharmaceutical Industries

Katerina Patavou is a graduate from the University of Reading with a bachelor degree in Law (LLB) and a masters in EU Law from Kings College London. With over 10 years of professional EU public affairs experience, she is an experienced consultant with a demonstrated history of working in the health and pharmaceutical industry. She finessed her business acumen during her tenure at Brussels based consultancies Burson Marsteller, DODS Europe and GPlus Europe after working as accredited assistant at the European Parliament. Since 2013, she is Head of EU Public Affairs and Social Impact Strategist for the Panhellenic Union of Pharmaceutical Industry, a national association member of Medicines for Europe representing 49 Greek pharmaceutical manufacturing companies with 45 production sites throughout Greece.

Maximilian Salcher-Konrad - Pharmaceutical Policy Researcher, Gesundheit Österreich GmbH

Maximilian Salcher-Konrad is a pharmaceutical policy researcher at the Pharmacoeconomics department at Gesundheit Österreich GmbH / Austrian National Public Health Institute. His current research focuses on the reimbursement, pricing, and procurement of medicines, as well community pharmacy, and encompasses both national and international studies. He holds an MSc in Health Policy, Planning and Financing from the London School of Economics and Political Science (LSE) and the London School of Hygiene and Tropical Medicine, and a BSc in Economics from the Vienna University of Economics and Business (WU). Maximilian has led and published original studies, systematic reviews and meta-analyses on a wide variety of health topics, including pharmaceutical regulation and policy, comparative effectiveness of health interventions, and evidence generation in different research areas.

Artur Cwiok - Head of Europe, Viatris

Artur Cwiok has over 31 years experience in the pharmaceutical industry. He has held senior leadership roles across Europe, leading in the innovative specialty sector and across all channels: generics, brands, OTC, retail, and hospital. Dr. Cwiok is currently serving as the Head of Europe for Viatris, one of the world's leading global pharmaceutical companies, empowering people worldwide to live healthier at every stage of life. Viatris is present in 38 countries in the European region and in more than 165 countries and territories globally. Dr. Cwiok actively represents his company in national and regional industry associations, helping shape policies that enable the European population to have access to high quality medicine. He is currently serving as a Member of the Executive Committee for Medicines for Europe. Dr. Cwiok is passionate about providing universal access to medicine and giving everyone the opportunity to live the healthiest life possible.

Philippe Drechsle - Vice President EU Portfolio, Teva & member of the Medicines for Europe executive committee

Economist and certified accountant by education, Philippe has been working in the generics industry for over 20 years in various functions spanning from controlling/finance, demand management, product administration, area management, business development, product portfolio optimization, to special projects such as FMD project lead. He is currently responsible for EU Portfolio, in charge of generics product selection, launches and life-cycle management.

Monica Dias - Head of the Supply and Availability of Medicines and Devices, European Medicines Agency (EMA)

Dr. Dias is Head of supply and availability of medicines and devices, at EMA since October 2021. She is responsible for the implementation of the extended mandate of EMA in the area of shortages of medicines and devices. She is Co-Chair of the HMA/EMA HMA/EMA TF AAM and she is the Chair of the Medicine Shortages SPOC Working Party and Medical Device Shortages SPOC Working Party. Dr. Dias studied pharmacy in Lisbon, Portugal and obtained her PhD from the University of Cardiff, UK. Dr. Dias joined the European Medicines Agency in 2004. She worked in the Quality Office for 10 years. In 2013 she joined the Office of the Deputy Executive Director at EMA where she was Principal Policy and Crisis Coordinating Officer. She was involved in the development of policies, best practice guidance for the anonymisation of clinical reports, and coordinated the Brexit operational preparedness activities at EMA, including the impact of Brexit on the availability of Centrally Authorised products. Dr Dias was also coordinating at EMA the activities of the HMA/EMA Task Force on the availability of authorised medicines since November 2016. During the COVID-19 pandemic Dr. Dias coordinated activities in relation to shortages due the pandemic both at EMA and with the NCAs. She was involved in the setting up the mechanisms to monitor shortages of medicines (EU Executive Steering Group on shortages) and was leading a Working Group which developed a common framework for forecasting demand data in the EU/EEA. Dr. Dias also lead the workstream on the List of critical medicinal products of the structural dialogue **on** security of medicines supply under the pharmaceutical strategy for Europe.

Harald Mische - Deputy Head of Unit, Medical Products; quality, safety, innovation, European Commission

Harald Mische is the Deputy Head of Unit “Medical products: quality, safety and innovation” in the European Commission’s Directorate-General for Health and Food Safety (DG SANTE). The unit is in charge of EU level policy developments on quality, availability and affordability of medicines and supervises important aspects of the implementation of EU legislation and of the Pharmaceutical Strategy for Europe. He joined DG SANTE in 2021, after serving for almost 20 years in the European Commission’s Directorate-General for Competition (DG COMP) in various positions - more recently, in the Pharma Unit dealing with EU antitrust enforcement and policy in the area of pharmaceuticals and health. Being a fully qualified lawyer, prior to joining the European Commission in 2002, Harald practiced EU competition and regulatory law as part of an international law firm in Brussels. He is a regular speaker on EU pharmaceuticals antitrust and regulatory issues and has authored various publications on this topic. Harald obtained a Ph.D. in EU Merger Control Law from the Eberhard-Karls-University of Tübingen, Germany.

Donald Lo - Director for Medicines Development at EATRIS and Scientific Lead of the REMEDI4ALL European Platform for Medicines Repurposing

Donald Lo is the Director for Medicines Development at EATRIS and Scientific Lead of the REMEDI4ALL European Platform for Medicines Repurposing. Don previously headed the Therapeutic Development Branch at the National Center for Advancing Translational Sciences at the US NIH. Over a 10-year period this group helped advance over 50 new drugs into clinical trials, with 2 drug approvals to date. Don joined the NIH following a 27-year academic career at Duke University Medical Center, during which time he also co-founded and led 2 biotechnology companies and a non-profit patient care organization for Huntington's disease, and served as science advisor for a venture philanthropy organization for brain cancer. Don is a graduate of the California Institute of Technology, received his PhD from Yale University, and conducted postdoctoral research at the Ludwig Institute for Cancer Research at University College London.

Aurelio Arias - Director, EMEA Thought Leadership, IQVIA

Aurelio creates topical and forward-looking strategic content relevant to pharma executives worldwide and publishes articles, blogs, and white papers on a regular basis. Aurelio's predominant focus is on off-patent markets where he generates evidence-led insights with a view to spark high-level discourse on biosimilars, generics and value added medicines.

Virginie Hivert - Therapeutic Development Director, EURORDIS

Joined EURORDIS in June 2014. Referent for EURORDIS' activities related to the development of medicines for people living with rare diseases, patient empowerment (e.g. EURORDIS Summer School) and patient engagement in medicines development. Between June 2014 and January 2022, she has served as Observer on the EMA Committee for Orphan Medicinal Products (COMP), her role was to support the three patient representatives who are members of the COMP and also to bring an additional link between the Committee Chair, vice-Chair, Members, EMA Orphan office, and the Rare Diseases Community. During this period, she was also chairing the Therapeutic Action Group (TAG) put in place by EURORDIS to give a platform for RD patient representatives who are members of the EMA Scientific Committees (COMP, Paediatric Committee – PDCO, Committee for Advanced Therapies – CAT, Pharmacovigilance and Risk Assessment Committee – PRAC) to exchange and reflect on transversal topics in an environment where confidentiality is ensured. From March 2019 to February 2022, she has been PRAC Alternate member representing patient organizations. Since June 2022, she has been appointed as one of the Civil Society representatives on the EMA Management Board.
At global level, she is involved in the International Rare Diseases Research Consortium (IRDiRC) since its inception in

2011, first on the side of the Scientific Secretariat (prior to joining EURORDIS), then as Member of the Therapies Scientific Committee and later as its vice-Chair (March 2017 -February 2021). She is now representing EURORDIS in the IRDiRC Consortium Assembly/Patient Advocacy Constituent Committee. During these years, she has been contributing to and/or leading on several taskforces (Repurposing, Orphan Drug Development Guidebook, etc). On top of these activities, she is involved in the development and the running of projects in which EURORDIS is partner (EUPATI, PARADIGM, c4c, etc), in the content development for EURORDIS events (ERTC, ECRD, etc) and in some of the activities of Rare Diseases International. Work experience: 20+ years of work experience in research and healthcare, including 14 years in the rare diseases field – hospital, research lab, academia, European Medicines Agency (as expert) and patient organization. Notably, prior to joining EURORDIS, she worked 6 years at Orphanet, the international database on rare diseases and orphan drugs (INSERM, France). Virginie holds a PharmD and a PhD in Biological Sciences and has previously worked in basic research, particularly on pathophysiological pathways in oncology. Virginie speaks French and English.

Hakim Yadi - CEO & Co-founder, Closed Loop Medicine

Hakim is a Co-Founder and Chief Executive Officer of Closed Loop Medicine (CLM). CLM is a healthcare technology company developing drug + digital combination products, transforming drug effectiveness through optimisation by providing every drug its real time digital companion. Hakim joined Closed Loop Medicine from the Northern Health Science Alliance Ltd, the pan-Northern health partnership which brought together for the first time 20 research-based NHS hospitals, the North's Academic Health Science Networks and Universities to collaborate on improving health outcomes across the North. Hakim started his career at IMS Health before joining PA Consulting, where he co-managed the company's translational medicine team. During his time at PA, he was seconded to the UK Government where he worked as the Chief Operations Officer and was a founding member of the UK Department of International Trade (DIT) Life Sciences Organisation (LSO). In this role, he helped to oversee the DIT's global life science inward investment strategy. He holds a PhD from the University of Cambridge and in 2017 he was awarded an OBE for services to Healthcare Technology and the Economy.

Nivedita Valentine, Associate Vice President, Product Innovation, Pharmanovia

Nivedita heads Product Innovation at Pharmanovia. Her role focusses on novel medicinal entities and the identification of life cycle management to revitalise, repurpose or re-engineer iconic brands. Prior to Pharmanovia, she led the Speciality Brands Franchise development function at Accord Healthcare. Nivedita has over 20 years' experience in the pharmaceuticals industry and has held senior management positions overseeing portfolio planning and business development across international markets. Nivedita is a member of the Medicines for Europe Sector Groups for Value Added Medicines, Orphan Medicines and Paediatric Medicines. In addition to this, she is actively involved in two of the IR Diseases Research Consortium) Task Forces created to tackle specific topics within rare els Task force to Support the Spectrum of Rare Disease R&D and the Task Force for Drug rare diseases.

Stella Kyriakides - Commissioner for Health and Food safety, European Commission

As European Commissioner for Health and Food Safety, Stella Kyriakides has been leading the Commission's work on the public health response to COVID-19. Commissioner Kyriakides is responsible for a number of initiatives in the area of health aiming to establish a strong European Health Union. These include Europe's Beating Cancer Plan, the implementation of the EU Pharmaceutical Strategy, the proposal for a European Health Data Space and the operationalisation of the EU4Health Programme. She is a strong advocate for mental health. Commissioner Kyriakides is also responsible for the 'Farm to Fork' strategy for sustainable food, covering every step in the transformation of the food chain from production to consumption. Her responsibilities include animal welfare, food safety and animal and plant health and leading the work to protect plant health and reducing dependency on pesticides. Since February 2022, Commissioner Kyriakides has been at the forefront of EU efforts to support Ukraine and its people in the area of health, including by supporting the protection of the physical and mental health of Ukrainian refugees arriving in Member States. In 2006-2019, she was elected to the Cyprus Parliament for the Democratic Rally party, of which she was the Vice-President for ten years. In 2011, she was appointed Head of the Cyprus Delegation to the Parliamentary Assembly of the Council of Europe (PACE). In 2017, she was elected President of the PACE, the fourth woman to hold this position in the history of the Assembly. She has been an active advocate on patients' rights, and on the rights of cancer patients, founding the first Cypriot breast cancer organisation Europa Cyprus, for which she served as President for over 15 years. She was elected President to the European Breast Cancer Coalition Europa Donna, and served on numerous European patient advocacy and scientific boards. She is the recipient of numerous awards from her community service in Cyprus and globally.

Hannah Armstrong - Life Sciences Strategy and Policy Consultant, Charles Rivers Associates

Hannah Armstrong is a Senior Associate in the Life Sciences Practice of Charles River Associates (CRA) based in London. CRA is an economic consultancy that specialises in public policy issues in the life sciences industry. In her role, Hannah is responsible for managing global life science policy engagements for a range of pharmaceutical trade associations and companies primarily in the areas of pricing and reimbursement and the economics of biopharmaceutical innovation. Her work has spanned across many disease areas and geographies. For many years, a key area of interest for Hannah and CRA has been antimicrobial resistance (AMR) and identifying new policy solutions for tackling the problem holistically and ensuring access to effective antibiotics both now and in the future.

Most recently, Hannah led the development of the report, "Strengthening the Sustainability of the Off-Patent Antibiotic Supply Chain" for the AMR Industry Alliance, published in February 2023. This report highlighted the critical role of off-patent antibiotics in tackling AMR and the need for policy intervention to ensure a sustainable supply continues to be available to patients in the future.

Erika Satterwhite - Past Chair IGBA Biosimilars Committee and Head of Global Policy, Viatris

Erika Satterwhite is Head of Global Policy at Viatris, a global healthcare company. Prior to joining Viatris in November 2020, Erika led Global Policy for Mylan, and spent the previous decade in policy roles in Washington D.C. and Brussels, Belgium. Erika serves on the Boards of the Global Fund to Fight AIDS, TB and Malaria, and the AMR Industry Alliance. Erika is a graduate of Georgetown University, and lives in New York.

Christine Årdal - Senior Researcher, Norwegian Institute of Public Health

Christine Årdal MBA PhD is a Senior Researcher at the Norwegian Institute of Public Health, with a research focus on the policy aspects of antimicrobial access and innovation. Årdal was previously the co-lead of the research and innovation work package for the European Union's Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI), which aimed to detail European strategies to improve access to antibiotics, both old and new. She will again serve as the co-lead of the access work package for the forthcoming EU-JAMRAI-2. She was also a co-lead in the DRIVE-AB research project which aimed to transform the way policymakers stimulate innovation, the sustainable use, and the equitable availability of novel antibiotics to meet unmet public health needs. She is the co-lead for the Programme Committee of the Oslo Medicines Initiative, aiming to improve access to innovative, high-priced medicines, and an active member of the Norwegian assessment of local production for critical antibiotics and the MIA-research project, examining supply chain solutions to improve access to medicines.

Agnes Marta Molnar - Deputy Head of Unit - Intelligence Gathering, Analysis and Innovation, Health Emergency Preparedness and Response, HERA, European Commission

Dr Agnes Molnar is currently leading the unit on intelligence gathering, analysis and innovation at the Health Emergency Preparedness and Response Authority. She joined the European Commission in 2014, and has worked on social and environmental determinants of health, preparedness and response to serious cross-border health threats and global health security. Agnes holds a degree in medicine, law and a PhD in public health and preventive medicine. She pursued post-doctoral research in health policy and systems and health impact assessment.

Suzette Kox - Secretary General, International Generic and Biosimilar Association

Suzette Kox is the first Secretary General of the International Generic and Biosimilar Medicines Association. She was nominated in January 2019, after 17 years in various functions at Medicines for Europe. Adopting a patient centric approach, IGBA works to improve patients' access to quality-assured, safe and cost-effective medicines by promoting competition and enabling innovation in the pharmaceutical sector and sustainable economic contributions for all stakeholders. Before joining the generic medicines industry in 1992, Suzette followed a hospital and retail pharmacy career. Along with a degree in pharmacy (Paris), she holds a postgraduate diploma in anatomy-pathology (Cochin Port Royal, Paris).

Sandra Nobre - Head of Global Business Development, Medicines Patent Pool

Sandra Nobre joined the Medicines Patent Pool, a United Nations Public Health Organization working to increase access to essential medicines in LMICs (low-middle income countries), in October 2018, as Head of Business Development. Sandra has had a 20-year successful career within the pharmaceutical industry in companies such as Pfizer and Novartis and spent her lasts 8 years in the industry as Senior Director, Global Business Development at Takeda. Acquired throughout her career she also has a deep knowledge of the global healthcare ecosystem that she fully integrates in her current Public Health oriented role. Sandra earned a Master of Science in Pharmaceutical Chemistry and post-graduated in Biotechnology having completed some years later a Diploma of Advanced Studies in Corporate Social Responsibility and an MBA in International Management. While in MPP Sandra was instrumental in strengthening its role in the HIV and other infectious diseases space and in securing new licensing deals namely for the 3 Covid oral anti-virals from Shionogi, MSD and Pfizer and the Long-Acting Cabotegravir injectable from ViiV. Sandra enjoys working internationally and integrates well with multicultural and multinational environments and passionately integrates in her way of operating procedures ethically leading to sustainability.

Lydia Amartey-Williams - Director of Corporate Partnerships, International Health Partners

Lydia Amartey-Williams is the Director of Corporate Partnerships at International Health Partners UK. In this role, she is responsible for managing the Corporate Partnerships team, which focuses on facilitating medical product donations in a compliant, needs-led environment. Lydia leads the team to work with their corporate partners to ensure best practice throughout the product donation process. Before joining IHP, Lydia has a career-long history in Corporate Partnerships, w largest healthcare charities in the UK. She is passionate about developing partnerships between orations to enable better access to medicine and strengthen health systems. Lydia has a keen e UN's SDG goals as well as supporting companies to reach their desired ESG outcomes.

Paul Tredwell - Executive Vice President, Accord Healthcare

Paul Tredwell is Executive Vice President (EVP) of Accord EMENA, one of the fastest-growing pharmaceutical companies and a significant provider of medicines to healthcare systems across Europe. Paul is responsible for leading the organisation, including three manufacturing sites in Europe, Accord's commercial operations spanning 25 country offices, and partnerships totalling nearly 50 countries. Over the past five years, Paul has developed and led the specialty division of Accord through a combination of novel in-house product and portfolio design and a best-in-class dynamic Business Development team performing exceptionally in licensing and M&A transactions. Paul has over 25 years of industry experience, with many notable achievements, from leading-edge digital technology and marketing to being the first in the industry to fully commercialise a portfolio of biosimilars in a regulated market, performing the first NICE submission and approval for a biosimilar and establishing market access for this, at the time, a new category of medicines. Paul has launched over 30 speciality brands into European markets, including orphan to GP-promoted brands. He has launched countless generics over his career in some of the world's most significant speciality and generic companies, making his experience unique. Passionate about bringing high-quality, assessable medicines to patients across Europe, Paul is dedicated to 'make it better' for patients via innovative ways to design, manufacture or acquire products to support patients and healthcare professionals with different options for a standard of care and including, augmented delivery, duration of action and novel formulations. A multiple award winner, Paul has led Accord to be crowned as the most decorated company in peer awards and, more recently, has also been instrumental in delivering an outstanding employee engagement score which is underpinned by his personal commitment to becoming a mentor at Accord to develop and grow talent within the organisation.

David Jauch - Vice President, Market Access, Government Affairs & CSR, Fresenius Kabi

David M. Jauch is responsible for Market Access, Government Affairs and Corporate Social Responsibility (CSR) at Fresenius Kabi. He is the Chair of the International Affairs Committee, Member of the Board of Medicines for Europe as well as a member of the Trade Committee of IGBA (International Generics and Biosimilar Association) and has been working in the generic industry for more than 10 years. David studied Business Administration at the University of Stuttgart in Germany, Tongji University in Shanghai, China and Seoul National University in Korea and holds an Executive Master in Business Management of Leeds University Business School in the UK.

Malgosia Maurer MD. MBA. - Health Policy Advisor, Polpharma Group

At present engaged as Group Health Policy Adviser at Polpharma Group, Amsterdam, Malgosia has been leading governmental affairs activities for Polpharma Group across all geographies, playing an active role in the development of harmonised, medicines provision systems in emerging markets. A physician by training, Malgosia gained professional postgraduate healthcare qualifications in France and USA, before holding a range of senior health policy and public affairs roles in the pharmaceutical industry in Central and Eastern Europe. As a Member of EFPIA Board she worked closely on transposition of EU legal framework and patient's access to medicines. Currently as member of Medicines for Europe board she has actively been involved with shaping policy for generic sector in Europe promoting medicines security, EU based manufacturing and digitalisation of the health provision. In a private capacity she has a keen interest in preventive medicine and pro-health nutrition.